Business Context and Reporting Period
Company: TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: TuHURA is a clinical-stage immuno-oncology company developing novel personalized cancer vaccines and tumor microenvironment modulators. The company's lead product candidate, IFx-2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company is preparing for a Phase 3 registration trial for IFx-2.0 in Merkel cell carcinoma.
Recent Corporate Action: On October 18, 2024, the company completed a reverse merger with Kintara Therapeutics, Inc. (Legacy TuHURA became the accounting acquirer). The company changed its name to TuHURA Biosciences, Inc. and trades under the symbol "HURA" on the Nasdaq Capital Market.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(21,682) | $(29,317) |
| Net Loss Attributable to Common Shareholders | $(22,650) | $(29,317) |
| Research & Development Expenses | $13,335 | $9,402 |
| General & Administrative Expenses | $4,314 | $4,145 |
| Cash and Cash Equivalents (Dec 31, 2024) | $12,657 | $3,665 |
| Accumulated Deficit (Dec 31, 2024) | $(111,125) | $(88,475) |
| Convertible Notes Payable | $0 | $2,324 |
Note: The 2023 net loss included a one-time $16.2 million charge for acquired in-process research and development (IPR&D) related to the TuHURA Biopharma asset acquisition.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $7.6 million year-over-year, primarily due to the absence of the $16.2 million IPR&D write-off recorded in 2023.
- Increased R&D Spend: Research and development expenses increased by $3.9 million (42%) to $13.3 million, driven by ongoing clinical development of IFx-2.0 and preclinical research for IFx-3.0 and MDSC targets.
- Debt Conversion: Approximately $31.3 million in convertible notes issued during 2024 were automatically converted into common stock upon the completion of the Kintara Merger in October 2024, eliminating interest expense associated with these notes for the remainder of the year.
- Liquidity Improvement: Cash and cash equivalents increased from $3.7 million to $12.7 million, bolstered by $29.8 million in net cash provided by financing activities (convertible notes and private placements).
Guidance, Outlook, and Risks
Outlook and Guidance
- Phase 3 Trial Timeline: The company expects to receive a Complete Response Letter (CRL) from the FDA lifting a partial clinical hold on its IFx-2.0 Phase 3 trial in the second quarter of 2025. Initiation of the trial is targeted for the second quarter of 2025, pending successful mixing studies and potency assay qualifications.
- Kineta Merger: On December 12, 2024, the company entered into a definitive agreement to acquire Kineta, Inc. The transaction is expected to close in the second quarter of 2025, subject to conditions including a financing transaction yielding at least $35 million in net proceeds.
- Cash Runway: Management believes existing cash resources, combined with anticipated payments from warrant exercise notes, will fund operations through the late fourth quarter of 2025. This excludes funds required for the Kineta Merger.
Risks and Contingencies
- Going Concern: The company has incurred recurring losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern without additional financing.
- Regulatory Uncertainty: The Phase 3 trial for IFx-2.0 is subject to a partial clinical hold regarding Chemistry, Manufacturing, and Controls (CMC) requirements. Failure to lift this hold could delay or prevent the trial.
- Financing Dependency: The Kineta Merger is contingent upon raising $35 million. Failure to secure this financing could result in the termination of the merger and a $1 million termination fee.
Key Facts for Investor Verification
- Phase 3 Trial Status: Verify the status of the FDA partial clinical hold and the timeline for lifting it (expected Q2 2025).
- Kineta Merger Financing: Confirm the company's progress in securing the required $35 million financing condition for the Kineta acquisition.
- Cash Burn Rate: Monitor monthly cash burn to validate the runway estimate through late Q4 2025.
- Warrant Exercise Notes: Track the repayment of the $3.0 million in secured promissory notes issued by shareholders in February 2025 to fund warrant exercises, due May 30, 2025.
- Intellectual Property: Review the status of the exclusive license agreements with Moffitt Cancer Center and West Virginia University Research Corporation regarding Delta Receptor technology.